The effect of gemcitabine in the treatment of rejection in experimental small intestine transplantation.
The aim of our study was to test the immunosuppressive effect of gemcitabine in monotherapy following heterotopic SBT in the rat. The BN and LEW rats were used as donors and recipients, respectively. Recipients were divided into 4 groups--group A without immunosuppression, group B treated with a therapeutic dose of tacrolimus, groups C and D treated with various doses of gemcitabine (100 and 150 microg/kg/day). Immunosuppression was administered once a day for 7 days after SBT, when the animals were sacrificed and a histological examination of grafts was performed. Only in group B no signs of acute rejection were seen. Significant differences (P < 0.01) were noted only between group B versus groups A, C, and D. No significant differences were demonstrated between groups A versus groups C, D and between group C versus group D. Monotherapy by gemcitabine (when administered at given doses) was not shown to be effective in preventing acute rejection in a rat model of heterotopic SBT.
Kudla
M
M
Department of Transplant Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. michal.kudla@centrum.cz
Kríz
J
J
Janotová
D
D
Girman
P
P
Mergental
H
H
Kocík
M
M
Honsová
E
E
Adamec
M
M
D000818:Animals; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D006084:Graft Rejection / Q000188:drug therapy*; D007165:Immunosuppression Therapy; D007421:Intestine, Small / Q000187:drug effects / Q000637:transplantation*; D008297:Male; D051381:Rats; D011914:Rats, Inbred BN; D014184:Transplantation, Homologous; D000093542:Gemcitabine
D003841:Deoxycytidine; D000093542:Gemcitabine